Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13949194 | 0.80 | CHRNB2 (0.42) | MAPTKMT2AMEN1SMN1; SMN2HSD17B10 | |
| SCHEMBL3314638 | 0.80 | MAPT (0.41) | MAPTKMT2AMEN1SMN1; SMN2HSD17B10 | |
| SCHEMBL24127481 | 0.79 | HSD17B10 (0.39) | MAPTKMT2AMEN1SMN1; SMN2HSD17B10 | |
| SCHEMBL18517596 | 0.79 | HSD17B10 (0.39) | MAPTKMT2AMEN1SMN1; SMN2HSD17B10 | |
| SCHEMBL616596 | 0.78 | KMT2A (0.56) | MAPTKMT2AMEN1SMN1; SMN2HSD17B10 | |
| SCHEMBL24127448 | 0.78 | MAPT (0.39) | MAPTKMT2AMEN1SMN1; SMN2HSD17B10 | |
| SCHEMBL2744311 | 0.78 | DPP4 (0.40) | MAPTKMT2AMEN1SMN1; SMN2HSD17B10 | |
| SCHEMBL6757495 | 0.78 | DPP4 (0.40) | MAPTKMT2AMEN1SMN1; SMN2HSD17B10 | |
| SCHEMBL19735105 | 0.76 | KMT2A (0.42) | MAPTKMT2AMEN1SMN1; SMN2HSD17B10 | |
| SCHEMBL13949144 | 0.76 | MEN1 (0.42) | MAPTKMT2AMEN1SMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | TYMS, ABCG2, UMPS | MAPT 2130/4885KMT2A 3784/4885MEN1 3480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.